The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
The Value of Serum CA 19-9 in Predicting Cholangiocarcinomas in Patients with Primary Sclerosing Cholangitis
Abstract
CA 19-9 has been used with questionable accuracy to aid diagnosis of cholangiocarcinoma complicating primary sclerosing cholangitis. We aimed to characterize the test properties of CA 19-9 and of a change in CA 19-9 over time in predicting cholangiocarcinoma. Charts of 208 patients were reviewed. Fourteen patients had cholangiocarcinoma. Median CA 19-9 was higher with cholangiocarcinoma (15 vs. 290 U/ml, p < 0.0001). A cutoff of 129 U/ml provided: sensitivity 78.6%, specificity 98.5%, adjusted positive predictive value 56.6% and negative predictive value 99.4%. The median change over time was 664 U/ml in cholangiocarcinoma compared to 6.7 U/ml in primary sclerosing cholangitis alone (p < 0.0001). A cutoff of 63.2 U/ml for change in CA 19-9 provided: sensitivity 90%, specificity 98% and positive predictive value 42%. Only 2 patients with cholangiocarcinoma were the candidates for curative therapy. In conclusion, the positive predictive value of an elevated CA 19-9 was 56.6%; only advanced cases were detected by this method.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They are of limited diagnostic sensitivity and specificity, either alone or in combination.124,126,128,301,302”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [128]
Citations
Cites
Increasing Incidence and Mortality of Primary Intrahepatic Cholangiocarcinoma in the United States
Patel, T. (2001) · Hepatology · doi:10.1053/jhep.2001.25087 · Cited by 1,010
Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.
Broomé, U., Olsson, R., Lööf, L., Bodemar, G., Hultcrantz, R., Danielsson, A., Prytz, H., Sandberg-Gertzén, H., Wallerstedt, S., & Lindberg, G. (1996) · Gut · doi:10.1136/gut.38.4.610 · Cited by 819 · cited 1×
“However, the prevalence of cholangiocarcinoma in autopsies or liver specimens of patients undergoing liver transplantation for PSC is as high as 41%, indicating that the usually quoted figures may underestimate the true prevalence of this cancer (4, 5).”
BackgroundGuidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document
Khan, S. A., Davidson, B. R., Goldin, R., Pereira, S. P., Rosenberg, W. M. C., Taylor-Robinson, S. D., Thillainayagam, A. V., Thomas, H. C., Thursz, M. R., & Wasan, H. (2002) · Gut · doi:10.1136/gut.51.suppl_6.vi1 · Cited by 648 · cited 2×
“Cholangiocarcinoma may be the initial presentation of PSC and approximately 5% of all cholangiocarcinomas are multifocal (1).”
BackgroundPrimary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential
Broomé, U., Löfberg, R., Veress, B., & Eriksson, L. S. (1995) · Hepatology · doi:10.1002/hep.1840220511 · Cited by 481 · cited 1×
“There is some evidence that cholangiocarcinoma is more frequent in smokers (7) and in those with CUC associated with colonic dysplasia or neoplasia (8).”
BackgroundPatel, A. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00744-3 · Cited by 425 · cited 1×
“Previous studies have demonstrated that high CA 19-9 correlates with the risk of developing cholangiocarcinoma in patients with (10, 14–16) or without PSC (17).”
Self-citationCholangiocarcinoma Complicating Primary Sclerosing Cholangitis
ROSEN, C. B., NAGORNEY, D. M., WIESNER, R. H., COFFEY, R. J., & LARUSSO, N. F. (1991) · Annals of Surgery · doi:10.1097/00000658-199101000-00004 · Cited by 391
Self-citationCholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study
Chalasani, N., Baluyut, A., Ismail, A., Zaman, A., Sood, G., Ghalib, R., McCashland, T. M., Reddy, R. K., Zervos, X., Anbari, M. A., et al. (2000) · Hepatology · doi:10.1002/hep.510310103 · Cited by 336 · cited 1×
“This finding has not been confirmed by other investigators (16) and was not the aim of our study, as most patients did not have a CEA measured.”
ResultElevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice
Mann, D., Edwards, R., Ho, S., Lau, W., & Glazer, G. (2000) · European Journal of Surgical Oncology (EJSO) · doi:10.1053/ejso.1999.0925 · Cited by 294 · cited 1×
“Levels of CA19-9 show a positive correlation with the bilirubin level or with other markers of cholestasis in patients with obstructive jaundice, making it difficult to interpret an elevated CA19-9 in this setting (20).”
BackgroundBergquist, A., Glaumann, H., Persson, B., & Broomé, U. (1998) · Hepatology · doi:10.1002/hep.510270201 · Cited by 281 · cited 1×
“There is some evidence that cholangiocarcinoma is more frequent in smokers (7) and in those with CUC associated with colonic dysplasia or neoplasia (8).”
BackgroundSerum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis
Ramage, J. K., Donaghy, A., Farrant, J. M., Iorns, R., & Williams, R. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90462-x · Cited by 279 · cited 1×
“In that study, a value >200 U/ml had sensitivity and specificity of 60 and 90%, respectively, in differentiating PSC versus PSC with cholangiocarcinoma (15).”
Background
Cited by
Razumilava, N., & Gores, G. J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61903-0 · Cited by 1,729
Self-citationCholangiocarcinoma — evolving concepts and therapeutic strategies
Ilyas, S. I., Khan, S. A., Hallemeier, C. L., Kelley, R. K., & Gores, G. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.157 · Cited by 1,626
Self-citationBanales, J. M., Cardinale, V., Carpino, G., Marzioni, M., Andersen, J. B., Invernizzi, P., Lind, G. E., Folseraas, T., Forbes, S. J., Fouassier, L., et al. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.51 · Cited by 1,376
Diagnosis and Management of Primary Sclerosing Cholangitis
Chapman, R., Fevery, J., Kalloo, A., Nagorney, D. M., Boberg, K. M., Shneider, B., & Gores, G. J. (2010) · Hepatology · doi:10.1002/hep.23294 · Cited by 1,224
Self-citationPrimary sclerosing cholangitis – a comprehensive review
Karlsen, T. H., Folseraas, T., Thorburn, D., & Vesterhus, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.022 · Cited by 868
“The utility of CA19-9 is only in combination with other modalities as it lacks sensitivity (low levels may be observed in advanced CCA) and specificity (elevated levels may be observed with cholangitis or other malignancies) (207).”
Background
Metadata
- Authors
- Levy, C., Lymp, J., Angulo, P., Gores, G. J., Larusso, N., & Lindor, K. D.
- Affiliations
- University of Florida Health (US)
- Mayo Clinic (US)
- Corresponding author
- Lindor, Keith D.
- Venue
- Digestive Diseases and Sciences
- Published
- 2005-09
- Volume
- 50
- Issue
- 9
- Pages
- 1734-1740
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2013099235
- Cited by
- 339
- References
- 23
- Citations by year
- 2026: 9 · 2025: 7 · 2024: 13 · 2023: 14 · 2022: 15 · 2021: 24 · 2020: 13 · 2019: 16 · 2018: 24 · 2017: 22 · 2016: 18 · 2015: 31 · 2014: 22 · 2013: 17 · 2012: 15
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mayo Clinic
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- CA19-9, cholangiocarcinoma, primary sclerosing cholangitis, tumor markers, cancer detection, diagnostic accuracy, serum biomarkers
- MeSH terms
- Bile Duct Neoplasms, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Reference Values, Cholangitis, Sclerosing, Cholangiocarcinoma, CA-19-9 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Value of Serum CA 19-9 in Predicting Cholangiocarcinomas in Patients with Primary Sclerosing Cholangitis. https://app.cochat.ai/papers/10.1007/s10620-005-2927-8
- The paper
- Levy, C., Lymp, J., Angulo, P., Gores, G. J., Larusso, N., & Lindor, K. D. (2005). The Value of Serum CA 19-9 in Predicting Cholangiocarcinomas in Patients with Primary Sclerosing Cholangitis. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-005-2927-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.